Resolution of statin-induced myalgia by correcting vitamin D deficiency: a case report
DOI:
https://doi.org/10.7175/cmi.v9i1.978Keywords:
Myalgia, Statin, Vitamin D, Vitamin supplementationAbstract
The onset of myalgia is a well-known side effect of cholesterol-lowering statins. Recent studiesa dvanced the hypothesis that reduced vitamin D levels may play a role in the onset of myalgia in statin users and potentially a vitamin D supplementation may be useful in these cases, as suggested by the present case report.
A 52-year-old man with a history of smoke and successfully controlled hypertension presented with chest pain and asthenia. He was diagnosed with stable angina pectoris and discharged on atorvastatin. Due to the onset of myalgia, the dosage of atorvastatin was reduced (from 40 mg daily to 20 mg daily) and then atorvastatin was switched to rosuvastatin without symptoms improvement. Switching from rosuvastatin to ezetimibe resulted in pain improvement, but also in plasma lipids increase beyond the normal range. Ezetimibe was switched to rosuvastatin+ analgesic; in the meanwhile a high-performance liquid chromatography (HPLC) analysis showed low levels of 25-hydroxy-vitamin D and 1-25-dihydroxy-vitamin D. Therefore, vitamin D3 was added to rosuvastatin, resulting in pain improvement, decrease of plasma lipids and progressive discontinuation of analgesics. During the follow-up, rosuvastatin was switched to atorvastatin + vitamin D3, with a good control of plasma lipid levels and without the onset of myalgia.
References
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-934; http://dx.doi.org/10.1016/j.jacc.2013.11.002
Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90; http://dx.doi.org/10.1016/S0140-6736(07)60716-8
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45; http://dx.doi.org/10.1038/clpt.1981.154
Palleria C, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 2013; 18: 601-10
Gallelli L, Ferraro M, Spagnuolo V, et al. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Drug Metabol Drug Interact 2009; 24: 83-7; http://dx.doi.org/10.1515/DMDI.2009.24.1.83
Settergren J, Eiermann B, Mannheimer B. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy–A Nationwide Register Study. PLoS ONE 2013; 8: e69545; http://dx.doi.org/10.1371/journal.pone.0069545
De Vuono A, Palleria C, Scicchitano F, et al. Skin rash during treatment with generic itraconazole. J Pharmacol Pharmacother 2014; 5: 158-60; http://dx.doi.org/10.4103/0976-500X.130086
Mumoli L, Gambardella A, Labate A, et al. Rosacea-like facial rash related to metformin administration in a young woman. BMC Pharmacol Toxicol 2014; 15: 3; http://dx.doi.org/10.1186/2050-6511-15-3
Morioka TY, Lee AJ, Bertisch S, et al. Vitamin D status modifies the association between statin use and musculoskeletal pain: A population based study. Atherosclerosis 2014; 238: 77-82; http://dx.doi.org/10.1016/j.atherosclerosis.2014.11.012
Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - A systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2014; 178C: 111-6; http://dx.doi.org/10.1016/j.ijcard.2014.10.118
Duell PB, Connor WE. Vitamin D deficiency is associatedwith myalgias in hyperlipidemic subjects taking statins. Circulation 2008; 118: 470
Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009; 153: 11-6; http://dx.doi.org/10.1016/j.trsl.2008.11.002
Bittner V, Wenger NK, Waters DD, et al. Vitamin D levels are not related to myalgias in statin-treated patients with stable coronary disease. J Am Coll Cardiol 2010; 55: 177-1659 (poster contribution); http://dx.doi.org/10.1016/S0735-1097(10)61571-9; http://dx.doi.org/10.1016/S0735-1097(10)61660-9
Mergenhagen K, Ott M, Heckman K, et al. Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. Clin Ther 2014; 36: 770-7; http://dx.doi.org/10.1016/j.clinthera.2014.02.023
Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006; 210: 94-102; http://dx.doi.org/10.1002/path.2018
Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporos Int 2002; 13: 187-94; http://dx.doi.org/10.1007/s001980200012
Al-Said YA, Al-Rached HS, Al-Qahtani HA, et al. Severe proximal myopathy with remarkable recovery after vitamin D treatment. Can J Neurol Sci 2009; 36: 336-9; http://dx.doi.org/10.1017/S0317167100007083
Binkley N, Gemar D, Engelke J, et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J Clin Endocrinol Metab 2011; 96: 981-8; http://dx.doi.org/10.1210/jc.2010-0015
Chaney A. Primary care management of vitamin D deficiency and liver disease. J Am Assoc Nurse Pract 2015 Feb 26 [Epub ahead of print]; http://dx.doi.org/10.1002/2327-6924.12217
Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014; 348: g1903; http://dx.doi.org/10.1136/bmj.g1903
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)